الفهرس 
ESTROGEN AND ESTROGEN RECEPTORSOnly 14 pages are availabe for public view
 |  | from | 214 |  |  |
| | | from | 214 | | |
Abstract
SUMMARY
This study was carried at Clinical Oncology and Cardiology Departments, Tanta University Hospitals, and included eighty female patients with estrogen receptor and/or progesterone receptor positive stages I–III invasive breast cancer who received hormonal treatment throughout the period from August 2016 to August 2018.
The aim of this study is to evaluate the association between incident cardiovascular disease and adjuvant endocrine therapy in postmenopausal endocrine-responsive breast cancer women and analyze the major risk factors.
Hormone receptor-positive (estrogen [ER] and/or progesterone [PR] receptor-positive) breast cancers comprise the most common types of breast cancer, accounting for 75 % of all cases.
Third generation aromatase inhibitors (AIs) have replaced tamoxifen as the mainstay treatment of estrogen-receptor (ER) positive breast cancer in postmenopausal women. Aromatase inhibitors significantly reduce breast cancer recurrence and breast cancer-related mortality and increase overall survival in comparison with tamoxifen.
Hormonal receptor positive breast cancer patients in this study were classified in two groups:-
- (group A), 45 patients during the 1st year of hormonal therapy.
- (group B), 35 patients during and after the 5th year of hormonal treatment.
In group A:- There was no significant difference as regard echocardiographic parameters, lipid profile between AI and